Consider Onstryv Another MAO-B Inhibitor for Parkinson's

September 2019

Onstryv (ON-striv, safinamide) will be a new add-on for Parkinson's disease.

Think of Onstryv as similar to selegiline or rasagiline (Azilect).

These selective MAO-B inhibitors prevent dopamine breakdown to reduce "off-time"...when carbidopa/levodopa wears off and symptoms worsen.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Hypertension Consider Nuances When Managing Hypertension in Older Adults
Diabetes Help Patients With Diabetes Decipher Continuous Glucose Monitor Metrics
Osteoporosis Advise Saving Evenity for High-Risk Women With Osteoporosis
ADHD Solve Common Dilemmas With ADHD Stimulants
Scabies Don't Recommend OTC Permethrin to Treat Scabies
Anticholinergics Look for Opportunities to Limit Anticholinergic Meds in Older Adults
Parkinson's Disease Consider Onstryv Another MAO-B Inhibitor for Parkinson's
Kidney Disease Emphasize Adherence With Phosphate Binders in Chronic Kidney Disease
Communication Up Your Communication Game With "SBAR"
Transplantation Ensure Transplant Patients Get the Right Tacrolimus Product
Pediatrics Navigate Requirements for Kids Who Need Back-to-School Rxs